BioVaxys Closes Third Tranche of Private Placement, Bolstering Financial Stability

BioVaxys Technology Corp. (BIOV) has announced the successful closing of the third tranche of its private placement, raising CAD 1 million in funding. This strategic move is expected to significantly enhance the company's financial stability and support its long-term growth initiatives. The private placement involved the issuance of 20,000,000 Units at a price of CAD 0.05 per Unit, with each Unit consisting of one common share and one whole Share purchase warrant exercisable at CAD 0.15 for a period of 24 months.

The proceeds from the third tranche will be used primarily for working capital purposes, enabling BioVaxys to maintain its operations and continue its research and development efforts. This additional funding is crucial for a clinical-stage biotechnology company like BioVaxys, as it allows the company to invest in its vaccine platforms and immuno-diagnostics, as well as advance its product pipeline.

BioVaxys' long-term growth strategy revolves around developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The company is focused on using its haptenized antigen technology platforms to develop vaccines for treating viral infections, such as SARS-CoV-2, human papillomavirus (HPV), and cancers like late-stage ovarian cancer, cervical cancer, and melanoma. Some of their product pipeline includes:

* BVX-0320: An investigational new drug (IND)-stage vaccine candidate for SARS-CoV-2, which is the recombinant S1 subunit of the spike protein of SARS-CoV-2 modified with a chemical called hapten, specifically, dinitrophenyl (DNP).
* CoviDTH: A disposable, diagnostic tool to identify a T-cell immune response to the presence of SARS-CoV-2.
* BVX-0918A: A haptenized tumor cell vaccine for ovarian cancer.

The use of proceeds from the private placement aligns with BioVaxys' long-term growth strategy, as the funds raised will support the company's working capital needs, enabling them to continue investing in their vaccine platforms and immuno-diagnostics, as well as advancing their product pipeline. This will ultimately help BioVaxys achieve its long-term goal of improving patient lives with novel immunotherapies.

In conclusion, the closing of the third tranche of BioVaxys' private placement is a significant milestone for the company, as it bolsters its financial stability and supports its long-term growth strategy. The additional funding will enable BioVaxys to continue investing in its vaccine platforms and immuno-diagnostics, ultimately helping the company achieve its goal of improving patient lives with novel immunotherapies.